Genzyme's Termeer loses millions at $69 per share

Genzyme CEO Henri Termeer (photo) may have a selfish reason for refusing Sanofi-Aventis' $69-per-share offer. Yes, Termeer would get a big buyout bonus--$11 million by some estimates--but that bonus plus his own stock-related gains wouldn't make up for the loss of future pay and the loss of upside on his stock options, the Wall Street Journal figures. Report